# MeiraGTx Holdings plc (MGTX)

> Source: Nexqual · https://nexqual.com/MGTX · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, MeiraGTx Holdings plc (MGTX), nexqual.com/MGTX" · informational, not investment advice.

**Price:** USD 9.71 (-0.46% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 9.75 · day 9.54–9.9 · 52w 6.62–15.35 · market cap $932M · NMS

## Key facts
- Valuation: P/E 11.9x, EV/EBITDA 4.6x, net cash $43.2M.
- Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 27.75 (range 16–50).
- Total return with dividends: 1Y +11.7% vs S&P 500 +14.8%; 5Y -54.9% vs S&P 500 +79.1%.
- Next earnings: 2026-11-12 (date not yet confirmed by the company), EPS estimate USD -0.47, revenue estimate $7.0M. All companies reporting that day: https://nexqual.com/earnings/2026-11-12
- Dividend: MGTX paid no cash dividend in the last five years.
- Short interest: 9.35% of float (as of 2026-10-15), 5.8 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 11.9x · P/S 2.4x · EV/EBITDA 4.6x · EV/Sales 2.3x · P/FCF 89.7x · P/B 4.3x · FCF yield 1.11% · Earnings yield 8.41% · Net cash $43.2M · EV $896M

## Analysts
Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 27.75 (low 16, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-24 | Goldman Sachs | Initiated | Neutral | $16 |
| 2026-08-14 | RBC Capital | Target raised | Outperform | $26 → $27 |
| 2026-07-08 | RBC Capital | Target raised | Outperform | $25 → $26 |
| 2026-07-08 | HC Wainwright & Co. | Reiterated | Buy | $20 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +11.7% | -54.9% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +11.8% | -14.7% |
| Volatility (annualized) | 57.7% | 69.4% |
| Max drawdown | -38.7% (Aug 2026→Oct 2026) | -84.4% (Dec 2021→Oct 2023) |

## Dividends
MGTX paid no cash dividend in the last five years.

## Short interest
6,438,544 shares sold short, 9.35% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 4,011,818 shares (+60.5%). Days to cover: 5.8 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/MGTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name MGTX in their own reports (relationship from MGTX's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Ocugen, Inc. (OCGN) | 10-K 2026-03-04 | "We are aware of several companies focusing on gene therapies for various ophthalmic indications including Applied Genetic Technologies Corporation, as acquired by Beacon Therapeutics, Astellas Pharma …" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.47 | $-0.50 | +$0.03 | $7.0M | 3 |
| Next quarter (ends 2026-12-31) | $-0.50 | $-0.27 | −$0.23 | $8.5M | 3 |
| Current fiscal year (ends 2026-12-31) | $0.51 | $-1.47 | +$1.98 | $337.1M | 3 |
| Next fiscal year (ends 2027-12-31) | $-1.52 | $-1.39 | −$0.13 | $66.9M | 4 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $2.52 | −$0.42 | Beat +$2.94 | — |
| — | Quarter ended Mar 31, 2026 | −$0.57 | −$0.45 | Miss −26.7% | — |
| — | Quarter ended Dec 31, 2025 | $0.19 | −$0.62 | Beat +$0.81 | — |
| — | Quarter ended Sep 30, 2025 | −$0.62 | −$0.49 | Miss −26.5% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).